肾脏疾病患者生存质量（K/DOQI）指南和改善全球肾脏病预后组织（KDIGO）指南推荐了慢性肾脏病患者全段血清甲状旁腺激素（iPTH）的靶目标值。但这些指南都是基于一些观察性的研究结论。目前尚未有临床随机对照试验显示通过治疗iPTH达到某一水平会改善慢性肾脏病患者的预后。也没有干预性的随机对照试验以确定iPTH指标和临床事件直接的因果效应关系。在不同的研究中有益的iPTH靶目标值水平不同，因此推测合适的iPTH水平目前仍然未知。就此，本文从以下五个方面对iPHT靶目标值进行再评价：关于iPTH靶目标值的国内外指南，按照K/DOQI指南建议的目标值iPTH 达标率低，K/DOQI指南用以设定iPTH靶目标值的证据强度不足，iPTH的检测方法尚不统一，iPTH增高和死亡率增加没有明显的直接关系。

K/DOQI guidelines and KDIGO guidelines have offered the recommended target value of intact parathyroid hormone (iPTH) in patients suffering from chronic kidney disease (CKD). These guidelines were based on the conclusions of some observational studies. Few randomized controlled trials (RCT) have shown that the treatment of CKD patients could lead to improved outcomes with iPTH reaching a certain level. Nor have interventional RCT trials been carried out to determine the direct causaleffect relationship between iPTH level and clinical events. The fact that most beneficial iPTH target value varied between various studies indicated that suitable iPTH levels still remains to be determined yet. In this commentary, several domestic and international guidelines concerning the most beneficial iPTH target value have been reviewed. The compliance rate of iPTH target value is low in accordance with K/DOQI guidelines. The evidence of K/DOQI guidelines for setting the iPTH target value is insufficient.The detection method of iPTH is not yet unified. There is no apparent direct relationship between increased iPTH level and increased mortality. So the iPTH target value needs a re-evaluation for the above five existing aspects.